Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Cash & Equivalents: 2018-2025

Historic Cash & Equivalents for Neurogene (NGNE) over the last 6 years, with Sep 2025 value amounting to $71.0 million.

  • Neurogene's Cash & Equivalents rose 6.56% to $71.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.0 million, marking a year-over-year increase of 6.56%. This contributed to the annual value of $136.6 million for FY2024, which is 7.84% down from last year.
  • Latest data reveals that Neurogene reported Cash & Equivalents of $71.0 million as of Q3 2025, which was up 20.73% from $58.8 million recorded in Q2 2025.
  • Neurogene's 5-year Cash & Equivalents high stood at $150.1 million for Q1 2024, and its period low was $25.2 million during Q3 2023.
  • In the last 3 years, Neurogene's Cash & Equivalents had a median value of $70.8 million in 2025 and averaged $82.3 million.
  • Per our database at Business Quant, Neurogene's Cash & Equivalents skyrocketed by 323.00% in 2024 and then tumbled by 52.86% in 2025.
  • Over the past 3 years, Neurogene's Cash & Equivalents (Quarterly) stood at $148.2 million in 2023, then decreased by 7.84% to $136.6 million in 2024, then increased by 6.56% to $71.0 million in 2025.
  • Its Cash & Equivalents stands at $71.0 million for Q3 2025, versus $58.8 million for Q2 2025 and $70.8 million for Q1 2025.